Source comparison
Hexarelin Half Life: Comparison Table
Hexarelin 70–90 minutes 45–60 minutes (receptor activation threshold) 2–3× daily, 6–8 hour intervals 20–30 minutes post-injection Shortest half life among GH secretagogues—provides precise temporal control but requires strict dosing compliance and cycling to p
This comparison does not assign a generated winner or score.
- Hexarelin
- 70–90 minutes
- 45–60 minutes (receptor activation threshold)
- 2–3× daily, 6–8 hour intervals
- 20–30 minutes post-injection
- Shortest half life among GH secretagogues—provides precise temporal control but requires strict dosing compliance and cycling to prevent desensitization
- GHRP-2
- 120 minutes
- 90 minutes
- 2–3× daily
- 30–45 minutes
- Slightly longer duration than hexarelin with less receptor desensitization; better for sustained protocols but lower peak GH amplitude
- Ipamorelin
- 120–150 minutes
- 90–120 minutes
- 2× daily
- Most selective GHS-R1a agonist with minimal desensitization; longer functional duration allows twice-daily dosing with consistent response over time
- CJC-1295 + Ipamorelin
- 6–8 days (CJC) / 120–150 min (Ipa)
- Sustained baseline + acute pulses
- CJC weekly, Ipamorelin 2× daily
- Ipamorelin peaks in 30–45 min
- Gold standard combination—CJC provides GHRH amplification, Ipamorelin delivers acute pulses; less desensitization than hexarelin-based stacks
- MK-677 (Ibutamoren)
- 4–6 hours
- 6–8 hours
- 1× daily
- 2–4 hours (sustained elevation, not acute pulse)
- Oral bioavailability and long half life allow once-daily dosing, but continuous GH elevation disrupts physiological pulsatility and may reduce receptor sensitivity over months